Scalable Milk-Derived Whey Protein Hydrogel as an Implantable Biomaterial

There are limited naturally derived protein biomaterials for the available medical implants. High cost, low yield, and batch-to-batch inconsistency, as well as intrinsically differing bioactivity in some of the proteins, make them less beneficial as common implant materials compared to their synthetic counterparts. Here, we present a milk-derived whey protein isolate (WPI) as a new kind of natural protein-based biomaterial for medical implants. The WPI was methacrylated at 100 g bench scale, >95% conversion, and 90% yield to generate a photo-cross-linkable material. WPI-MA was further processed into injectable hydrogels, monodispersed microspheres, and patterned scaffolds with photo-cross-linking-based advanced processing methods including microfluidics and 3D printing. In vivo evaluation of the WPI-MA hydrogels showed promising biocompatibility and degradability. Intramyocardial implantation of injectable WPI-MA hydrogels in a model of myocardial infarction attenuated the pathological changes in the left ventricle. Our results indicate a possible therapeutic value of WPI-based biomaterials and give rise to a potential collaboration between the dairy industry and the production of medical therapeutics.

Automated summary

There is a need for more naturally derived protein biomaterials for medical implants. In this study, milk-derived whey protein isolate (WPI) was developed as a new natural protein-based biomaterial for medical implants. The WPI was modified and processed into injectable hydrogels, microspheres, and scaffolds using advanced techniques. In vivo evaluation showed promising biocompatibility and effectiveness in attenuating pathological changes. These findings suggest the potential therapeutic value of WPI-based biomaterials and opportunities for collaboration between the dairy industry and medical therapeutics production.